US Pharma MarketingAstellas touts data from early test of stem cell-derived eye therapy
Astellas reported its stem cell-derived therapy improved vision at low and medium doses in a Phase 1b geographic atrophy trial, but high-dose data raised questions. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene…
Astellas reported promising results with its stem cell-derived therapy in an age-related eye disease, though data in a handful of high-dose patients in the early-stage study raised questions.
The experimental stem cell therapy is made ...
Source: Endpoints News